Camlin Fine

how big is Camlin Fine?

As of October 2023, Camlin Fine Sciences Ltd has a market capitalization of 4,852.00 Cr, categorizing it as a Small Cap company, with recent net sales of 1,687.30 Cr and a net profit of -139.04 Cr over the last four quarters. Shareholder's funds are 864.75 Cr, and total assets amount to 1,911.22 Cr as of March 2024.

Market Cap: Camlin Fine Sciences Ltd has a market capitalization of 4,852.00 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters, which includes Mar'25, Dec'24, Sep'24, and Jun'24, is 1,687.30 Cr. The sum of Net Profit for the same quarters is -139.04 Cr. This data is Consolidated.<BR><BR>Balance Sheet Snapshot: This is Consolidated data for the latest annual period ending in Mar'24. Shareholder's Funds are reported at 864.75 Cr, and Total Assets amount to 1,911.22 Cr.

Who are in the management team of Camlin Fine?

As of March 2023, the management team of Camlin Fine includes Ashish S Dandekar (Chairman & Managing Director), Nirmal V Momaya (Managing Director), and several directors and independent directors, totaling 11 key members who guide the company's governance and strategy.

As of March 2023, the management team of Camlin Fine includes the following members:<BR><BR>1. Ashish S Dandekar - Chairman & Managing Director<BR>2. Nirmal V Momaya - Managing Director<BR>3. Anagha S Dandekar - Director<BR>4. Arujun S Dukane - Executive Director (Technical)<BR>5. Amol Shah - Independent Director<BR>6. Sutapa Banerjee - Independent Director<BR>7. Mahabaleshwar G Palekar - Independent Director<BR>8. Harsha Raghavan - Director<BR>9. Conrad D Souza - Independent Director<BR>10. Pradip M. Kanakia - Independent Director<BR>11. Rahul Sawale - Vice President & Company Secretary<BR><BR>This diverse team encompasses various roles, including executive, independent, and director positions, contributing to the company's governance and strategic direction.

What does Camlin Fine do?

Camlin Fine Sciences Ltd is a small-cap company in the specialty chemicals industry, originally established in 1993. As of March 2025, it reported net sales of 437 Cr and a net profit of -1 Cr, with a market cap of Rs 4,933 Cr.

Overview: <BR>Camlin Fine Sciences Ltd operates in the specialty chemicals industry and is categorized as a small-cap company.<BR><BR>History: <BR>The company was originally incorporated on November 30, 1993, as Camlicon Consultants Private Limited. It underwent a name change to Camlin Fine Chemicals Private Limited on June 1, 2006, following the demerger of the Fine Chemicals Division from Camlin Limited, effective July 1, 2006. The latest quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 437 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -1 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 4,933 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 138.00 <BR>Industry P/E: 47 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.54 <BR>Return on Equity: 3.83% <BR>Price to Book: 5.28 <BR><BR>Contact Details: <BR>Address: Plot No F/11 & F/12 WICEL, Central Road Andheri(East) Mumbai Maharashtra : 400093 <BR>Tel: 91-22-67001000 <BR>Email: secretarial@camlinfs.com <BR>Website: http://www.camlinfs.com

Has Camlin Fine declared dividend?

Yes, Camlin Fine Sciences Ltd has declared a dividend of 45% (0.45 per share) with an ex-date of July 28, 2016. However, the current dividend yield is 0%, despite significant price appreciation over the past five years.

Camlin Fine Sciences Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 45%<BR>- Amount per share: 0.45<BR>- Ex-date: 28 Jul 16<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6 months period, the price return was 121.16%, with a dividend return of 0%, resulting in a total return of 121.16%.<BR><BR>In the 1 year period, the price return was 181.64%, with a dividend return of 0%, resulting in a total return of 181.64%.<BR><BR>In the 2 years period, the price return was 58.52%, with a dividend return of 0%, resulting in a total return of 58.52%.<BR><BR>In the 3 years period, the price return was 132.74%, with a dividend return of 0%, resulting in a total return of 132.74%.<BR><BR>In the 4 years period, the price return was 51.6%, with a dividend return of 0%, resulting in a total return of 51.6%.<BR><BR>In the 5 years period, the price return was 518.24%, with a dividend return of 0%, resulting in a total return of 518.24%.<BR><BR>Overall, while Camlin Fine has declared a dividend in the past, the current dividend yield is 0%. However, the total returns over various periods demonstrate significant price appreciation, particularly over the 5-year period.

Who are the peers of the Camlin Fine?

Camlin Fine's peers include Pidilite Industries, SRF, Gujarat Fluoroch, Deepak Nitrite, Himadri Special, Rossari Biotech, Vishnu Chemicals, S H Kelkar & Co., Nocil, and Bhansali Engineering. Camlin Fine has below average management risk, growth, and capital structure compared to its peers, with a notable 1-year return of 163.83%.

Peers: The peers of Camlin Fine are Pidilite Inds., SRF, Gujarat Fluoroch, Deepak Nitrite, Himadri Special, Rossari Biotech, Vishnu Chemicals, S H Kelkar & Co., Nocil, and Bhansali Engg.<BR><BR>Quality Snapshot: Excellent management risk is observed at Deepak Nitrite, Pidilite Inds., Rossari Biotech, and SRF, while Good management risk is found at Vishnu Chemicals and Himadri Special. Average management risk is present at Gujarat Fluoroch, S H Kelkar & Co., and Nocil, while Camlin Fine has Below Average management risk. For Growth, Excellent growth is seen at Himadri Special, while Average growth is noted at Pidilite Inds., Rossari Biotech, and SRF. Below Average growth is found at Gujarat Fluoroch, Deepak Nitrite, S H Kelkar & Co., and Nocil, while Camlin Fine has Below Average growth. In terms of Capital Structure, Excellent capital structure is noted at Pidilite Inds., Deepak Nitrite, and Rossari Biotech, while Good capital structure is observed at Himadri Special, Gujarat Fluoroch, and S H Kelkar & Co. Camlin Fine has Below Average capital structure.<BR><BR>Return Snapshot: Himadri Special has the highest 1-year return at 40.96%, while Deepak Nitrite has the lowest at -9.60%. Camlin Fine's 1-year return is significantly higher at 163.83%. Additionally, the peers with negative six-month returns include Deepak Nitrite, Nocil, and Rossari Biotech.

Who are the top shareholders of the Camlin Fine?

The top shareholders of Camlin Fine include promoters with the largest individual holding by Ashish Subhash Dandekar at 10.52%, mutual funds at 3.38%, foreign institutional investors at 2.88%, and individual investors collectively owning 30.98%, with Nirmal Vinod Momaya as the highest public shareholder at 1.92%.

The top shareholders of Camlin Fine include the promoters, who hold the majority of the shares. Among them, Ashish Subhash Dandekar has the highest individual holding at 10.52%. Additionally, mutual funds collectively hold 3.38% of the shares through six schemes, while foreign institutional investors (FIIs) hold 2.88% through 48 different entities. The highest public shareholder is Nirmal Vinod Momaya, who holds 1.92%. Individual investors collectively own 30.98% of the company.

When is the next results date for Camlin Fine?

The next results date for Camlin Fine is 10 November 2025.

The next results date for Camlin Fine is scheduled for 10 November 2025.

How has been the historical performance of Camlin Fine?

Camlin Fine's historical performance has been mixed, with net sales increasing to 1,666.53 Cr in Mar'25 but a significant decline in profitability, resulting in a net loss of -139.05 Cr. While total assets grew, cash flow from operations decreased, indicating inconsistent financial health.

Answer:<BR>The historical performance of Camlin Fine shows a mixed trend over the years, with significant fluctuations in key financial metrics.<BR><BR>Breakdown:<BR>Camlin Fine's net sales increased from 1,412.09 Cr in Mar'22 to 1,666.53 Cr in Mar'25, although it peaked at 1,681.56 Cr in Mar'23. Total operating income followed a similar pattern, reaching 1,666.53 Cr in Mar'25. However, total expenditure also rose, reaching 1,458.41 Cr in Mar'25, up from 1,259.29 Cr in Mar'22. Operating profit (PBDIT) showed some improvement, increasing to 222.57 Cr in Mar'25 from 185.83 Cr in Mar'22, but profit before tax declined significantly to 49.03 Cr in Mar'25 from 94.11 Cr in Mar'22. The net profit turned negative in Mar'25 at -139.05 Cr, down from 60.68 Cr in Mar'22. The company's total assets increased to 1,958.75 Cr in Mar'25 from 1,763.70 Cr in Mar'22, while total liabilities also rose to 1,958.75 Cr in Mar'25 from 1,763.70 Cr in Mar'22. Cash flow from operating activities decreased to 26.00 Cr in Mar'25 from 145.00 Cr in Mar'22, and the closing cash and cash equivalents improved to 104.00 Cr in Mar'25 from 107.00 Cr in Mar'22. Overall, while revenues have shown growth, profitability has been inconsistent, leading to a negative net profit in the latest fiscal year.

Is Camlin Fine overvalued or undervalued?

As of November 25, 2025, Camlin Fine's valuation has shifted from attractive to fair, indicating it is overvalued with a PE ratio of 327.96 and an EV to EBITDA of 19.86, especially when compared to peers like Solar Industries and Godrej Industries.

As of 25 November 2025, the valuation grade for Camlin Fine has moved from attractive to fair. Based on the analysis, the company appears to be overvalued. Key ratios indicate this, with a PE ratio of 327.96, an EV to EBITDA of 19.86, and a ROE of only 0.98%. <BR><BR>In comparison to its peers, Camlin Fine's valuation metrics stand out unfavorably; for instance, Solar Industries has a PE of 90.94 and an EV to EBITDA of 55.97, while Godrej Industries, which is rated attractive, has a PE of 35.73 and an EV to EBITDA of 39.89. Additionally, despite a strong performance year-to-date with a return of 19.77% compared to the Sensex's 8.25%, the long-term outlook shows a decline over three years, further supporting the notion that Camlin Fine is currently overvalued.

Is Camlin Fine technically bullish or bearish?

As of December 3, 2025, Camlin Fine's technical trend has shifted to a moderate bearish stance, driven by bearish momentum in the MACD, confirming moving averages, and Bollinger Bands, despite mixed signals from the KST.

As of 3 December 2025, the technical trend for Camlin Fine has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. Key indicators driving this include the weekly MACD showing bearish momentum, daily moving averages confirming a bearish trend, and Bollinger Bands indicating bearish conditions on both weekly and monthly time frames. The KST presents a mixed signal with a bearish weekly reading and a bullish monthly reading, but overall, the prevailing bearish indicators suggest a downward pressure on the stock.

Are Camlin Fine Sciences Ltd latest results good or bad?

Camlin Fine Sciences Ltd's latest results are concerning, showing a consolidated net loss of ₹36.23 crores in Q3 FY26, a 775.12% decline year-on-year, despite a 6.07% increase in net sales. The company faces significant operational challenges, with rising costs and a collapsing operating margin, indicating a negative financial outlook.

Camlin Fine Sciences Ltd's latest results are concerning. In the third quarter of FY26, the company reported a consolidated net loss of ₹36.23 crores, which is a significant deterioration compared to the previous year, reflecting a staggering 775.12% decline year-on-year. While net sales increased by 6.07% to ₹457.20 crores, this revenue growth has not translated into profitability, as the operating margin collapsed to 4.82%, down from 13.40% a year earlier.<BR><BR>The company's financial struggles are further highlighted by a nine-month performance for FY26, where total consolidated losses reached ₹60.57 crores, indicating ongoing operational challenges. The rising employee costs, which increased by 33.06% year-on-year, have outpaced revenue growth, suggesting inefficiencies within the organization.<BR><BR>Overall, the results indicate a company grappling with severe operational issues, mounting losses, and a lack of clear pathways to recovery. The financial metrics paint a picture of distress rather than stability, making the latest results decidedly negative.

Should I buy, sell or hold Camlin Fine Sciences Ltd?

Why is Camlin Fine Sciences Ltd falling/rising?

As of 04-Mar, Camlin Fine Sciences Ltd's stock price is at 139.60, reflecting a decline of 2.95%. The stock is underperforming with a significant drop in profits and investor interest, indicating a bearish trend and weak long-term fundamentals.

As of 04-Mar, Camlin Fine Sciences Ltd's stock price is falling, currently at 139.60, which reflects a decrease of 4.25 (-2.95%). The stock has been underperforming significantly, with a consecutive fall over the last two days, resulting in a total decline of 5.99% during this period. Additionally, the stock is trading below its moving averages across various timeframes, indicating a bearish trend.<BR><BR>Investor participation has also decreased, as evidenced by a 26.82% drop in delivery volume compared to the five-day average. This decline in trading activity suggests waning interest among investors. Furthermore, the company's financial performance has been troubling, with a staggering 97.4% drop in profits over the past year, contributing to a negative return of -6.21% in the same timeframe. The company's weak long-term fundamentals, including a high Debt to EBITDA ratio of 3.61 times and a low Return on Equity of 5.57%, further exacerbate the situation.<BR><BR>Overall, the combination of poor financial results, declining investor interest, and underperformance relative to benchmarks has led to the stock's current downward trajectory.

Which are the latest news on Camlin Fine?